ABUS Arbutus Biopharma Corporation - Common Stock

NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗
$4.74
मूल्य · अग 18, 2026
मौलिकता इस प्रकार है अग 12, 2026
52W रेंज
$3–$5
68% of range
विश्लेषक रेटिंग
BUY
8 analysts
मूल्य लक्ष्य
$6
+17% upside
P/E (TTM)
-28.5
ROE
-42.0%
शुद्ध लाभ मार्जिन
-237.9%

Arbutus Biopharma Corporation - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

और पढ़ें

Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

History

Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.

Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).

Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.

Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.

Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.

Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.

On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.

Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.

The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.

In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.

In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.

In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.

COVID-19

On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.

Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.

स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗

Wikidata ↗

ABUS स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा

मूल्य
$4.74
मार्केट कैप
$934M
P/E (TTM)
-28.5
EPS (TTM)
$-0.17
राजस्व (TTM)
$14M
लाभांश प्रतिफल
—
ROE
-42.0%
D/E ऋण/इक्विटी
—
52W रेंज
$3 – $5

ABUS स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें

10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान

राजस्व और शुद्ध आय $14M
10-point trend, +844.5%
2016-12-31 → 2025-12-31
EPS $-0.17
9-point trend, +97.7%
2016-12-31 → 2025-12-31
फ्री कैश फ्लो $-40M
9-point trend, +35.9%
2016-12-31 → 2025-12-31
मार्जिन -237.9%

मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?

मेट्रिक
5Y रुझान
ABUS
सहकर्मी माध्यिका
P/E (TTM)
5-point trend, -503.7%
-28.5
6.7
P/S (TTM)
5-point trend, +28.1%
66.3
39.8
P/B
5-point trend, +263.3%
12.2
4.8
Price / FCF (मूल्य / FCF)
5-point trend, -183.1%
-23.6
—

लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC

मेट्रिक
5Y रुझान
ABUS
सहकर्मी माध्यिका
Operating Margin (परिचालन मार्जिन)
5-point trend, +59.5%
-271.0%
—
Net Profit Margin (शुद्ध लाभ मार्जिन)
5-point trend, +65.7%
-237.9%
-220.1%
ROA
5-point trend, +33.7%
-29.6%
-35.0%
ROE
5-point trend, +17.5%
-42.0%
-43.2%

वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती

मेट्रिक
5Y रुझान
ABUS
सहकर्मी माध्यिका
Current Ratio (वर्तमान अनुपात)
5-point trend, +9.8%
15.7
9.7
Quick Ratio (त्वरित अनुपात)
5-point trend, +11.1%
15.5
—

विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR

मेट्रिक
5Y रुझान
ABUS
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
5-point trend, +28.2%
128.2%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
5-point trend, +28.2%
-28.8%
—
Revenue CAGR 5Y (राजस्व CAGR 5Y)
5-point trend, +28.2%
15.3%
—

प्रति शेयर मेट्रिक्स EPS, प्रति शेयर बुक वैल्यू, प्रति शेयर नकदी प्रवाह, प्रति शेयर लाभांश

मेट्रिक
5Y रुझान
ABUS
सहकर्मी माध्यिका
EPS (Diluted) (EPS (तनुभूत))
5-point trend, +79.5%
$-0.17
—

पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर

मेट्रिक
5Y रुझान
ABUS
सहकर्मी माध्यिका

ABUS विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड

खरीदें 8 विश्लेषक
  • मजबूत खरीद 3 37.5%
  • खरीदें 4 50.0%
  • होल्ड 1 12.5%
  • बेचें 0 0.0%
  • मजबूत बिक्री 0 0.0%

12-महीने का मूल्य लक्ष्य

1 विश्लेषक · 2026-08-17
मध्यिका लक्ष्य $5.53 +16.6%
माध्य लक्ष्य $5.53 +16.6%

Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि

औसत आश्चर्य
0.01%
Period EPS Actual EPS अनुमान आश्चर्य
31 मार्च 2026 $-0.05 $-0.03 -0.02%
31 दिसमबर 2025 $-0.02 $-0.04 0.02%
30 सितमबर 2025 $-0.04 $-0.03 -0.01%
30 जून 2025 $0.01 $-0.05 0.06%
31 मार्च 2025 $-0.13 $-0.11 -0.02%
31 दिसमबर 2024 $-0.07 $-0.08 0.01%

सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी

टिकर मार्केट कैप P/E राजस्व YoY शुद्ध मार्जिन ROE सकल मार्जिन
ABUS $926M -28.3 128.2% -237.9% -42.0% —
XENE $3.59B -10.3 — -4612.1% -56.9% —
AUPH $2.11B 7.7 20.4% 101.5% 62.7% —
ZYME $1.97B -24.4 38.9% -76.6% -26.9% —
ACOG $141M -5.5 — -202.2% -43.8% —

पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह

आय विवरण 16
ABUS के लिए वार्षिक आय विवरण डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Revenue 11-point trend, -39.5% $14M $6M $18M $39M $11M $7M $6M $6M $11M $1M $23M
R&D Expense 11-point trend, -51.0% $25M $54M $74M $84M $66M $49M $58M $58M $63M $61M $52M
SG&A Expense 11-point trend, -39.9% $16M $22M $22M $18M $17M $15M $18M $16M $16M $39M $26M
Operating Expenses 11-point trend, -58.9% $52M $82M $96M $104M $85M $65M $150M $96M $122M $493M $127M
Operating Income 11-point trend, +63.3% $-38M $-76M $-78M $-65M $-74M $-58M $-144M $-90M $-111M $-492M $-104M
Interest Expense 9-point trend, +459000.00 · · $459.0K $2M $3M $4M $2M $226.0K $261.0K $0 $0
Interest Income 11-point trend, +503.6% $4M $7M $6M $2M $127.0K $741.0K $2M $3M $2M $1M $674.0K
Other Non-op 11-point trend, -81.4% $5M $6M $5M $444.0K $-3M $-6M $-22M $28M $2M $2M $25M
Pretax Income 6-point trend, +19.2% · · · · · $-64M $-166M $-61M $-109M $-489M $-79M
Income Tax 11-point trend, +100.0% $0 $0 $0 $4M $0 $0 $-13M $-4M $-24M $-105M $-16M
Net Income 11-point trend, +46.6% $-34M $-70M $-73M $-69M $-76M $-64M $-154M $-57M $-84M $-384M $-63M
EPS (Basic) 10-point trend, +87.7% $-0.17 $-0.38 $-0.44 $-0.46 $-0.83 $-1.00 · $-1.21 $-1.56 $-7.24 $-1.38
EPS (Diluted) 10-point trend, +87.7% $-0.17 $-0.38 $-0.44 $-0.46 $-0.83 $-1.00 · $-1.21 $-1.56 $-7.24 $-1.38
Shares (Basic) 10-point trend, +321.4% 191,599,600 185,608,874 165,960,379 150,939,337 106,242,452 75,835,378 · 55,304,083 54,723,272 53,074,401 45,462,324
Shares (Diluted) 10-point trend, +321.4% 191,599,600 185,608,874 165,960,379 150,939,337 106,242,452 75,835,378 · 55,304,083 54,723,272 53,074,401 45,462,324
EBITDA 9-point trend, +92.2% $-38M $-76M $-78M $-65M $-74M $-58M · $-90M $-111M $-492M ·
बैलेंस शीट 25
ABUS के लिए वार्षिक बैलेंस शीट डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Cash & Equivalents 11-point trend, -89.2% $18M $36M $26M $31M $109M $52M $32M $37M $54M $23M $167M
Short-term Investments 11-point trend, +405.8% $73M $86M $100M $116M $46M $71M $59M $88M $72M $107M $15M
Receivables 11-point trend, +43.6% $1M $2M $2M $1M $899.0K $1M $1M $1M $402.0K $273.0K $1M
Prepaid Expense 11-point trend, +28.6% $2M $2M $4M $3M $4M $3M $2M $3M $2M $1M $1M
Current Assets 11-point trend, -48.6% $94M $127M $132M $151M $161M $128M $94M $129M $129M $133M $184M
PP&E (Net) 11-point trend, -99.0% $32.0K $3M $5M $5M $6M $7M $9M $10M $12M $7M $3M
PP&E (Gross) 11-point trend, -98.1% $245.0K $16M $17M $16M $15M $15M $14M $17M $25M $18M $13M
Accum. Depreciation 11-point trend, -97.8% $213.0K $13M $12M $11M $9M $8M $6M $7M $13M $11M $10M
Goodwill 5-point trend, -100.0% · · · · · · $0 $22M $24M $24M $163M
Intangibles 5-point trend, -100.0% · · · · · · $0 $44M $59M $99M $353M
Other Non-current Assets 8-point trend, +130000.00 $130.0K $34.0K $0 $103.0K $61.0K $44.0K $293.0K $0 · · ·
Total Assets 11-point trend, -86.7% $95M $132M $144M $195M $204M $137M $106M $228M $237M $276M $712M
Accounts Payable 11-point trend, -38.2% $5M $8M $10M $16M $11M $9M $7M $9M $11M $10M $9M
Current Liabilities 11-point trend, -43.2% $6M $16M $22M $33M $11M $10M $8M $11M $15M $11M $11M
Capital Leases 8-point trend, +199000.00 $199.0K $806.0K $1M $2M $2M $3M $3M $0 · · ·
Deferred Tax 5-point trend, -100.0% · · · · · · $0 $13M $17M $41M $146M
Total Liabilities 11-point trend, -89.0% $18M $34M $38M $59M $35M $35M $33M $28M $55M $73M $165M
Long-term Debt Flat — no change across 5 periods $0 $0 $0 $0 $0 · · · · · ·
Common Stock 11-point trend, +70.4% $1.42B $1.41B $1.35B $1.32B $1.29B $986M $899M $879M $876M $867M $834M
Paid-in Capital 11-point trend, +175.8% $83M $82M $81M $72M $65M $61M $55M $48M $43M $37M $30M
Retained Earnings 11-point trend, -416.9% $-1.38B $-1.35B $-1.28B $-1.20B $-1.13B $-1.05B $-970M $-805M $-738M $-653M $-267M
AOCI 11-point trend, +3.4% $-48M $-48M $-48M $-50M $-48M $-48M $-48M $-48M $-48M $-48M $-50M
Stockholders' Equity 11-point trend, -86.0% $77M $97M $106M $137M $169M $102M $73M $200M $182M $203M $548M
Liabilities + Equity 11-point trend, -86.7% $95M $132M $144M $195M $204M $137M $106M $228M $237M $276M $712M
Shares Outstanding 11-point trend, +252.8% 192,531,225 189,963,492 169,867,414 157,455,363 144,987,736 89,678,722 64,780,314 55,518,800 55,060,650 54,841,494 54,570,691
नकदी प्रवाह 14
ABUS के लिए वार्षिक नकदी प्रवाह डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Stock-based Comp 9-point trend, -54.0% $7M $9M $9M $7M $6M $6M $7M $6M $15M · ·
Deferred Tax 6-point trend, +100.0% · · · · · $0 $-13M $-4M $-24M $-105M $-16M
Restructuring 8-point trend, +12939000.00 $13M $4M $0 · $0 $64.0K $156.0K $5M $0 · ·
Operating Cash Flow 11-point trend, +29.7% $-40M $-65M $-86M $-35M $-68M $-51M $-71M $-68M $-49M $-58M $-56M
CapEx 11-point trend, -100.0% $0 $182.0K $1M $512.0K $809.0K $229.0K $589.0K $1M $7M $4M $2M
Investing Cash Flow 11-point trend, +102.8% $16M $23M $51M $-75M $-13M $-15M $28M $-4M $28M $-99M $8M
Debt Issued 3-point trend, +0.00 · · · · · · · · $0 $12M $0
Net Debt Issued 2-point trend, -100.0% · · · · · · · · $0 $12M ·
Stock Issued 7-point trend, -5.3% · · · · $135M $86M $19M $0 $0 $0 $142M
Net Stock Activity 4-point trend, +134665000.00 · · · · $135M $86M · · $0 $0 ·
Financing Cash Flow 11-point trend, -96.0% $6M $52M $31M $32M $137M $87M $37M $56M $49M $13M $144M
Net Change in Cash 11-point trend, -119.4% $-18M $10M $-4M $-79M $57M $20M $-5M $-17M $31M $-143M $95M
Free Cash Flow 9-point trend, +35.9% $-40M $-65M $-87M $-36M $-68M $-52M · $-69M $-56M $-62M ·
Levered FCF 3-point trend, +0.8% · · · · · $-56M · $-69M $-56M · ·
लाभप्रदता 7
ABUS के लिए वार्षिक लाभप्रदता डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Operating Margin 9-point trend, +99.2% -271.0% -1236.7% -430.5% -167.8% -669.1% -836.1% · -1510.2% -1036.7% -32973.8% ·
Net Margin 9-point trend, +99.1% -237.9% -1133.0% -401.6% -178.0% -693.9% -922.0% · -959.8% -788.9% -25765.5% ·
Pretax Margin 4-point trend, +97.2% · · · · · -922.0% · -1031.8% -1016.2% -32807.9% ·
EBITDA Margin 9-point trend, +99.2% -271.0% -1236.7% -430.5% -167.8% -669.1% -836.1% · -1510.2% -1036.7% -32973.8% ·
ROA 9-point trend, +61.9% -29.6% -50.6% -42.9% -34.7% -44.6% -52.5% · -24.5% -32.9% -77.8% ·
ROE 9-point trend, +59.0% -42.0% -68.5% -64.6% -49.2% -50.9% -64.0% · -27.5% -43.8% -102.4% ·
ROIC 4-point trend, +70.2% · · · · · -56.7% · -41.7% -47.2% -190.2% ·
तरलता और शोधन क्षमता 3
ABUS के लिए वार्षिक तरलता और शोधन क्षमता डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Current Ratio 9-point trend, +25.6% 15.7 8.2 5.9 4.6 14.3 13.4 · 11.5 8.8 12.5 ·
Quick Ratio 9-point trend, +25.2% 15.5 8.0 5.7 4.5 13.9 13.1 · 11.2 8.7 12.4 ·
Interest Coverage 6-point trend, +60.0% · · -170.2 -37.9 -25.7 -14.4 · -397.3 -425.0 · ·
दक्षता 2
ABUS के लिए वार्षिक दक्षता डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Asset Turnover 9-point trend, +4046.7% 0.1 0.0 0.1 0.2 0.1 0.1 · 0.0 0.0 0.0 ·
Receivables Turnover 9-point trend, +213.8% 7.3 2.9 11.6 34.7 9.9 5.5 · 6.5 31.7 2.3 ·
प्रति शेयर 5
ABUS के लिए वार्षिक प्रति शेयर डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Book Value / Share 9-point trend, -89.3% $0.40 $0.51 $0.62 $0.87 $1.17 $1.14 · $3.61 $3.31 $3.70 ·
Revenue / Share 8-point trend, +161.6% $0.07 $0.03 $0.11 $0.26 $0.10 · · $0.11 $0.20 $0.03 ·
Cash Flow / Share 8-point trend, +81.0% $-0.21 $-0.35 $-0.52 $-0.23 $-0.64 · · $-1.23 $-0.89 $-1.09 ·
Cash / Share 9-point trend, -78.1% $0.09 $0.19 $0.15 $0.20 $0.75 $0.58 · $0.67 $0.99 $0.43 ·
EPS (TTM) 11-point trend, +87.7% $-0.17 $-0.38 $-0.44 $-0.46 $-0.83 $-1.00 $-1.32 $-1.21 $-1.56 $-7.24 $-1.38
विकास दरें 3
ABUS के लिए वार्षिक विकास दरें डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Revenue YoY 5-point trend, +117.6% 128.2% -66.0% -53.5% 255.1% 58.9% · · · · · ·
Revenue CAGR 3Y 3-point trend, -175.9% -28.8% -17.5% 37.9% · · · · · · · ·
Revenue CAGR 5Y 15.3% · · · · · · · · · ·
मूल्यांकन (TTM) 10
ABUS के लिए वार्षिक मूल्यांकन (TTM) डेटा
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Revenue TTM 11-point trend, -39.5% $14M $6M $18M $39M $11M $7M $6M $6M $11M $1M $23M
Net Income TTM 11-point trend, +46.6% $-34M $-70M $-73M $-69M $-76M $-64M $-154M $-57M $-84M $-384M $-63M
Market Cap 9-point trend, +589.2% $926M $621M $425M $367M $564M $318M · $213M $278M $134M ·
P/E 11-point trend, -777.4% -28.3 -8.6 -5.7 -5.1 -4.7 -3.5 -2.1 -3.2 -3.2 -0.3 -3.2
P/S 9-point trend, -27.0% 65.8 100.7 23.4 9.4 51.3 46.0 · 35.8 26.0 90.1 ·
P/B 9-point trend, +1727.1% 12.1 6.4 4.0 2.7 3.3 3.1 · 1.1 1.5 0.7 ·
P / Tangible Book 6-point trend, +287.3% 12.1 6.4 4.0 2.7 3.3 3.1 · · · · ·
P / Cash Flow 9-point trend, -906.5% -23.4 -9.6 -4.9 -10.4 -8.4 -6.2 · -3.1 -5.7 -2.3 ·
P / FCF 9-point trend, -976.0% -23.4 -9.6 -4.9 -10.2 -8.3 -6.2 · -3.1 -5.0 -2.2 ·
Earnings Yield 11-point trend, +88.6% -3.5% -11.6% -17.6% -19.7% -21.3% -28.2% -47.5% -31.6% -30.9% -295.5% -31.0%

वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष

आय विवरण
2025-12-312024-12-312023-12-312022-12-312021-12-31
राजस्व $14M$6M$18M$39M$11M
परिचालन मार्जिन % -271.0%-1236.7%-430.5%-167.8%-669.1%
शुद्ध आय $-34M$-70M$-73M$-69M$-76M
तनुकरणित EPS $-0.17$-0.38$-0.44$-0.46$-0.83
बैलेंस शीट
2025-12-312024-12-312023-12-312022-12-312021-12-31
वर्तमान अनुपात 15.78.25.94.614.3
त्वरित अनुपात 15.58.05.74.513.9
नकदी प्रवाह
2025-12-312024-12-312023-12-312022-12-312021-12-31
फ्री कैश फ्लो $-40M$-65M$-87M$-36M$-68M

ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां

मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ

📊

उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।

आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।

संस्थागत मालिक (13F) 191 फाइलर्स · $496.0M कुल · तिथि अनुसार 30 जून 2026

संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।

संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
नई स्थितियाँ बाहर निकली पोजीशन बढ़ाया घटा हुआ शुद्ध शेयर परिवर्तन
41 (+15 पिछली तिमाही की तुलना में) 22 (-8 पिछली तिमाही की तुलना में) 55 (+10 पिछली तिमाही की तुलना में) 44 (-8 पिछली तिमाही की तुलना में) +14.8M

Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।

संस्था मूल्य शेयर % ट्रैक किए गए 13F का प्रकार
Two Seas Capital LP $91658798 19095583 18.48% शेयर
Whitefort Capital Management, LP $75812453 15794261 15.28% शेयर
VANGUARD GROUP INC $38412670 7986002 7.74% शेयर
STATE STREET CORP $37772059 7869179 7.62% शेयर
Rubric Capital Management LP $36158098 7532937 7.29% शेयर
VANGUARD CAPITAL MANAGEMENT LLC $33651259 7010679 6.78% शेयर
GEODE CAPITAL MANAGEMENT, LLC $16983987 3537471 3.42% शेयर
BlackBarn Capital Partners LP $12000000 2500000 2.42% शेयर
Woodline Partners LP $10952909 2281856 2.21% शेयर
GOLDMAN SACHS GROUP INC $8545829 1780381 1.72% शेयर
Jefferies Financial Group Inc. $8216026 1711672 1.66% शेयर
NOMURA HOLDINGS INC $7857989 1637081 1.58% शेयर
VANGUARD PORTFOLIO MANAGEMENT LLC $7398998 1541458 1.49% शेयर
BANK OF AMERICA CORP /DE/ $7169851 1493719 1.45% शेयर
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $6869846 1431218 1.38% शेयर
OSAIC HOLDINGS, INC. $6469756 1347866 1.30% शेयर
ADAR1 Capital Management, LLC $6087106 1268147 1.23% शेयर
Deltroit Asset Management (UK) LLP $5760000 1200000 1.16% शेयर
VANGUARD FIDUCIARY TRUST CO $5449738 1135362 1.10% शेयर
CITIGROUP INC $4175784 869955 0.84% शेयर
BANK OF MONTREAL /CAN/ $3734102 777938 0.75% शेयर
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $3123360 650700 0.63% शेयर
MACKENZIE FINANCIAL CORP $2946269 613806 0.59% शेयर
LOS ANGELES CAPITAL MANAGEMENT LLC $2889638 602008 0.58% शेयर
Western Standard LLC $2605378 542787 0.53% शेयर
Rangeley Capital, LLC $2400000 500000 0.48% शेयर
Man Group plc $2272642 473467 0.46% शेयर
Corbin Capital Partners, L.P. $2231732 682487 0.45% शेयर
CenterBook Partners LP $2136725 445151 0.43% शेयर
Freestone Capital Holdings, LLC $2124000 442500 0.43% शेयर
CITADEL ADVISORS LLC $1942541 404696 0.39% शेयर
KENNEDY CAPITAL MANAGEMENT LLC $1849430 385298 0.37% शेयर
Swiss National Bank $1375200 286500 0.28% शेयर
Ledgewood Wealth Advisors, LLC $1336493 278436 0.27% शेयर
FMR LLC $1277232 266090 0.26% शेयर
Susquehanna Portfolio Strategies, LLC $1265688 263685 0.26% शेयर
Carrera Capital Advisors $1234402 257167 0.25% शेयर
Quinn Opportunity Partners LLC $1225027 255214 0.25% शेयर
D. E. Shaw & Co., Inc. $1209614 252003 0.24% शेयर
STATE OF WISCONSIN INVESTMENT BOARD $1161682 242017 0.23% शेयर
Campbell & CO Investment Adviser LLC $1106563 230534 0.22% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1080475 225099 0.22% शेयर
Squarepoint Ops LLC $999096 208145 0.20% शेयर
MARTINGALE ASSET MANAGEMENT L P $926880 193100 0.19% शेयर
RHUMBLINE ADVISERS $909224 189423 0.18% शेयर
STRS OHIO $810720 168900 0.16% शेयर
Bank of New York Mellon Corp $801067 166889 0.16% शेयर
Caption Management, LLC $720000 150000 0.15% कॉल ऑप्शन
Caption Management, LLC $720000 150000 0.15% पुट ऑप्शन
Hudson Bay Capital Management LP $720000 150000 0.15% शेयर
Wealth Management Associates, Inc. $710376 147995 0.14% शेयर
WELLINGTON MANAGEMENT GROUP LLP $701467 146139 0.14% शेयर
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $643433 142985 0.13% शेयर
ALLIANCEBERNSTEIN L.P. $631080 140240 0.13% शेयर
Connor, Clark & Lunn Investment Management Ltd. $619685 129101 0.12% शेयर
BlackRock, Inc. $567398 118208 0.11% शेयर
Front Row Advisors LLC $516035 110500 0.10% शेयर
BARCLAYS PLC $499320 104025 0.10% शेयर
Rafferty Asset Management, LLC $490416 102170 0.10% शेयर
MetLife Investment Management, LLC $452885 94351 0.09% शेयर
VANGUARD ASSET MANAGEMENT, Ltd $429994 89582 0.09% शेयर
TWO SIGMA INVESTMENTS, LP $407933 84986 0.08% शेयर
JBF Capital, Inc. $385349 80281 0.08% शेयर
Integrated Quantitative Investments LLC $383698 79937 0.08% शेयर
Virtus Investment Advisers, LLC $368674 76807 0.07% शेयर
XTX Topco Ltd $365808 76210 0.07% शेयर
AMERICAN CENTURY COMPANIES INC $317832 66215 0.06% शेयर
Invesco Ltd. $305616 63670 0.06% शेयर
Rockefeller Capital Management L.P. $302400 63000 0.06% शेयर
Creative Planning $298133 62111 0.06% शेयर
JANUS HENDERSON GROUP PLC $273746 60900 0.06% शेयर
Quantinno Capital Management LP $273413 56961 0.06% शेयर
Zurcher Kantonalbank (Zurich Cantonalbank) $265118 55233 0.05% शेयर
Vanguard Global Advisers, LLC $264730 55152 0.05% शेयर
Mitsubishi UFJ Asset Management Co., Ltd. $255936 53320 0.05% शेयर
Jump Financial, LLC $255178 53162 0.05% शेयर
PROFUND ADVISORS LLC $254482 53017 0.05% शेयर
WOLVERINE TRADING, LLC $248868 55800 0.05% कॉल ऑप्शन
Police & Firemen's Retirement System of New Jersey $248203 51709 0.05% शेयर
Exome Asset Management LLC $240797 50166 0.05% शेयर
Magnetar Financial LLC $225922 47067 0.05% शेयर
State of New Jersey Common Pension Fund D $221602 46167 0.04% शेयर
MANUFACTURERS LIFE INSURANCE COMPANY, THE $212664 44305 0.04% शेयर
ALLSTATE CORP $212285 44226 0.04% शेयर
Quadrature Capital Ltd $201619 42004 0.04% शेयर
Universal- Beteiligungs- und Servicegesellschaft mbH $189475 39474 0.04% शेयर
ARIZONA STATE RETIREMENT SYSTEM $189110 39398 0.04% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $175680 36600 0.04% कॉल ऑप्शन
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $171936 35820 0.03% शेयर
NEW YORK STATE COMMON RETIREMENT FUND $169286 35268 0.03% शेयर
INTECH INVESTMENT MANAGEMENT LLC $167208 34835 0.03% शेयर
Mitsubishi UFJ Trust & Banking Corp $152102 31688 0.03% शेयर
VOYA INVESTMENT MANAGEMENT LLC $151070 31473 0.03% शेयर
China Universal Asset Management Co., Ltd. $150902 31438 0.03% शेयर
Vanguard Investments Australia, Ltd. $150182 31288 0.03% शेयर
KLP KAPITALFORVALTNING AS $148320 30900 0.03% शेयर
Premier Path Wealth Partners, LLC $144000 30000 0.03% शेयर
BNP PARIBAS FINANCIAL MARKETS $139675 29099 0.03% शेयर
SHERBROOKE PARK ADVISERS LLC $134627 27989 0.03% शेयर
EntryPoint Capital, LLC $134112 27940 0.03% शेयर

कंपनी के अंदरूनी सूत्र 25 इनसाइडर्स · 13 अधिकारी · 11 निदेशक

अंदरूनी भूमिका अंतिम गतिविधि शेयरों का स्वामित्व खरीद 12m बिक्री 12m नेट 12m
William H. Collier President and CEO 24 जून 2019 A — 0 0 $0
Mark J. Murray President and CEO 1 मार्च 2019 A 341396 0 0 $0
David C Hastings Chief Financial Officer 1 मार्च 2019 A — 0 0 $0
Bruce Cousins EVP & Chief Financial Officer 24 मार्च 2017 A — 0 0 $0
Gaston Picchio Chief Development Officer 1 मार्च 2019 A — 0 0 $0
Elizabeth Howard Executive VP & General Counsel 1 मार्च 2019 A — 0 0 $0
Michael J. Mcelhaugh Chief Business Officer 1 मार्च 2019 A — 0 0 $0
Michael J. Sofia Chief Scientific Officer 1 मार्च 2019 A 1503403 0 0 $0
Koert Vandenenden Chief Accounting Officer 11 दिसमबर 2018 A — 0 0 $0
William T. Symonds Chief Development Officer 16 अप्रैल 2018 A — 0 0 $0
Peter Lutwyche Chief Technology Officer 24 मार्च 2017 A — 0 0 $0
Michael J. Abrams Managing Director 16 अगस्त 2016 M 42097 0 0 $0
Mark Kowalski Sr VP & Chief Medical Officer 15 मार्च 2016 A — 0 0 $0
Roger Sawhney निदेशक 8 जून 2026 A — 0 0 $0
Robert A Beardsley निदेशक 8 जून 2026 A — 0 0 $0
Frank Torti निदेशक 26 नवमबर 2018 A — 0 0 $0
Vivek Ramaswamy निदेशक 19 जून 2018 A — 0 0 $0
Keith S Manchester निदेशक 19 जून 2018 A — 0 0 $0
Daniel D Burgess निदेशक 19 जून 2018 A — 0 0 $0
Herbert J Conrad निदेशक 19 जून 2018 A — 0 0 $0
Richard C Henriques JR निदेशक 19 जून 2018 A 1000 0 0 $0
Frank Karbe निदेशक 21 जून 2017 A — 0 0 $0
Roivant Sciences Ltd. 10% मालिक 18 अक्टूबर 2021 C 38847462 0 0 $0
Andrew Lo 10% मालिक 12 जनवरी 2018 P — 0 0 $0
Patrick Machado 10% मालिक 12 जनवरी 2018 P — 0 0 $0

SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S

कार्यकर्ता और 5%+ मालिक 8 होल्डिंग्स

जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।

फाइलर दाखिल किया दांव स्थिति उद्देश्य फाइलिंग
Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 फाइलिंग 28 अप्रैल 2026 8.00% संशोधन — SEC
Roivant Sciences Ltd. ×14 फाइलिंग 25 फ़रवरी 2025 20.50% संशोधन — SEC
Patrick Machado ×4 फाइलिंग 17 जुलाई 2019 — प्रारंभिक फाइलिंग — SEC
Dr. Andrew Lo ×5 फाइलिंग 17 जुलाई 2019 — प्रारंभिक फाइलिंग — SEC
QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 फाइलिंग 12 जुलाई 2019 — प्रारंभिक फाइलिंग — SEC
SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 फाइलिंग 12 जुलाई 2019 — प्रारंभिक फाइलिंग — SEC
Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 फाइलिंग 12 जुलाई 2019 — प्रारंभिक फाइलिंग — SEC
Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 फाइलिंग 12 जुलाई 2019 — प्रारंभिक फाइलिंग — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ईटीएफ स्वामित्व 34 ETFs द्वारा धारित

वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।

फंड भार इकाइयाँ तिथि अनुसार स्रोत
BBC · ETFis Series Trust I 0.66% 58600 NS 30 अप्रैल 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0.50% 24523 SH 8 अगस्त 2026 दैनिक
IWC · iShares Trust 0.17% 546359 SH 8 अगस्त 2026 दैनिक
LABU · Direxion Shares ETF Trust 0.11% 132235 NS 30 अप्रैल 2026 N-PORT
SMMV · iShares Trust 0.10% 62236 SH 8 अगस्त 2026 दैनिक
IBBQ · Invesco Exchange-Traded Fund Trust … 0.06% 10748 SH 8 अगस्त 2026 दैनिक
IBB · iShares Trust 0.06% 1164301 SH 8 अगस्त 2026 दैनिक
VTWG · VANGUARD SCOTTSDALE FUNDS 0.05% 172487 SH 8 अगस्त 2026 दैनिक
IWO · iShares Trust 0.04% 1441824 SH 8 अगस्त 2026 दैनिक
BIB · ProShares Trust 0.04% 7110 NS 31 मई 2026 N-PORT
GSSC · Goldman Sachs ETF Trust 0.03% 64366 NS 31 मई 2026 N-PORT
IWM · iShares Trust 0.02% 4026921 SH 8 अगस्त 2026 दैनिक
VTWO · VANGUARD SCOTTSDALE FUNDS 0.02% 925044 SH 8 अगस्त 2026 दैनिक
PRFZ · Invesco Exchange-Traded Fund Trust 0.02% 122366 SH 8 अगस्त 2026 दैनिक
RSSL · Global X Funds 0.02% 65520 NS 30 अप्रैल 2026 N-PORT
ITWO · ProShares Trust 0.02% 7126 NS 31 मई 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0.01% 734401 NS 31 मई 2026 N-PORT
ISCG · iShares Trust 0.01% 24628 SH 8 अगस्त 2026 दैनिक
ISCB · iShares Trust 0.01% 6673 SH 8 अगस्त 2026 दैनिक
UWM · ProShares Trust 0.01% 5554 NS 31 मई 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0.01% 1810587 SH 8 अगस्त 2026 दैनिक
VHT · VANGUARD WORLD FUND 0.01% 430244 SH 8 अगस्त 2026 दैनिक
FHLC · FIDELITY COVINGTON TRUST 0.01% 64437 NS 30 अप्रैल 2026 N-PORT
ISCV · iShares Trust 0.01% 13314 SH 8 अगस्त 2026 दैनिक
WSML · iShares Trust 0.01% 11503 SH 8 अगस्त 2026 दैनिक
URTY · ProShares Trust 0.01% 5639 NS 31 मई 2026 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.00% 5309 NS 31 मई 2026 N-PORT
HDG · ProShares Trust 0.00% 141 NS 31 मई 2026 N-PORT
ITOT · iShares Trust 0.00% 266009 SH 8 अगस्त 2026 दैनिक
IWV · iShares Trust 0.00% 49253 SH 8 अगस्त 2026 दैनिक
SCHB · SCHWAB STRATEGIC TRUST 0.00% 86163 NS 31 मई 2026 N-PORT
AVSC · AMERICAN CENTURY ETF TRUST 0.00% 4760 NS 31 मई 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0.00% 5034547 SH 8 अगस्त 2026 दैनिक
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 13683 SH 8 अगस्त 2026 दैनिक